← Back

ENvue Medical Inc.

ENvue Medical, Inc., through its subsidiaries, develops non-invasive biological response-activating devices for biofilm prevention, pain therapy, wound healing, and at-home use without medical professional assistance. Its products include UroShield and UroShield Ultra, ultrasound-based devices designed to prevent bacterial colonization and biofilm in urinary catheters, and PainShield, PainShield MD, and PainShield Plus, patch-based therapeutic ultrasound technologies for pain, muscle spasm, and joint contractures. The company also offers WoundShield, a patch-based therapeutic ultrasound device intended to support tissue regeneration and wound healing. Products are sold directly to patients and through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally. ENvue Medical, Inc. was formerly known as NanoVibronix, Inc., changed its name in December 2025, was incorporated in 2003, and is based in Tyler, Texas.

Price · split & dividend adjusted
News & notes moving FEED
FEED▼

ENvue Medical Denied Nasdaq Listing Appeal, Stock Moves to OTC Markets

ENvue Medical, Inc. said the Nasdaq Hearings Panel denied its request for continued listing on The Nasdaq Capital Market, and trading of its common stock will be suspended and begin on the OTC Markets under the same symbol, FEED, on September 16, 2026. The company said the Panel's decision does not affect its business operations, products, customers, or ongoing commercial activities, and that it remains focused on advancing commercialization of the ENvue Navigation System along with PainShield and UroShield. ENvue said it is evaluating all available procedures and alternatives under the Nasdaq Listing Rules, including a further appeal. Chief Executive Officer Doron Besser said the company is disappointed with the Panel's decision and is evaluating all available paths forward, while its team remains focused on customers, products and strategy execution. The company said it intends to provide additional information regarding the Nasdaq process and the trading status of its common stock as appropriate.
FEED ▼
GlobeNewswire·3dRead more →
FEED▲

ENvue Medical secures up to $50 million equity facility to fund growth

ENvue Medical has entered into a securities purchase agreement with an institutional investor for an equity facility of up to $50 million, subject to stockholder approval. The funding will support the expansion of its ENvue feeding tube navigation system, the development of next-generation navigation and AI technologies, and potential acquisitions. CEO Doron Besser said the company wants to expand beyond its current enteral navigation business by adding technologies, products, or businesses that can accelerate growth. The company's near-term focus is on expanding its hospital base, increasing use of its system, and growing recurring feeding tube revenue. ENvue said it plans to focus capital on opportunities it believes can support commercial and top-line growth and long-term shareholder value.
FEED ▲
Seeking Alpha·37dRead more →
Robotics & Physical AI▲

ENvue Medical unveils first robotic-assisted AI feeding tube automation tool

ENvue Medical has successfully developed and demonstrated the first prototype of ENvue Drive, a robotic-assisted tool that integrates artificial intelligence and real-time navigation for bedside feeding tube placement. The prototype, which incorporates the company's proprietary AI navigation software Ask Oscar, was able to identify anatomical pathways, detect trajectory deviations, provide corrective guidance, and assist advancement to a target position in the small intestine under clinician supervision. ENvue Drive is built on the FDA-cleared ENvue Navigation Platform and is designed as a platform architecture to eventually support both enteral and vascular access procedures, with future extensions planned for neonatal care and urinary access. The device remains an investigational prototype and has not been submitted to the FDA for clearance or approval.
FEED ▲
Robotics & Physical AI
GlobeNewswire·71dRead more →
© 2026 MarketDXAsset